Palatin Technologies, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013. Although the request identifies 2012 Q4, this filing is the FY2013 annual report; it also reports the quarter ended June 30, 2013.
Business context
Palatin is a development-stage biopharmaceutical company with no commercial product revenue. Its lead candidate is on-demand injectable bremelanotide for female sexual dysfunction (FSD). Other programs include PL-3994 for pulmonary and cardiovascular indications, MC1R peptide candidates, and melanocortin compounds licensed to AstraZeneca for metabolic conditions.
Financial results and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $10,000 | $74,000 |
| Research and development expense | $10.5 million | $13.8 million |
| General and administrative expense | $5.1 million | $5.0 million |
| Operating loss | $15.6 million | $18.8 million |
| Net loss | $20.9 million | $17.3 million |
| Net loss per share | $0.21 | $0.49 |
| Cash used in operating activities | $13.6 million | $15.5 million |
Cash, cash equivalents and short-term investments were $24.4 million at June 30, 2013, versus $3.8 million of cash and no short-term investments a year earlier. Current liabilities were $2.1 million; total liabilities were $2.1 million, including approximately $20,000 of capital lease obligations. The filing reports no off-balance-sheet arrangements. The company had an accumulated deficit of $260.1 million. Gross margin is not meaningful for this pre-commercial company.
The July 2012 private placement generated $34.4 million in net proceeds. Management believed available capital could fund planned operations through at least calendar 2014, but not Phase 3 enrollment and completion. The estimated Phase 3 program cost, through NDA submission, was at least $78 million.
Material changes and unusual items
- Revenue remained immaterial and fell from $74,000 to $10,000; all license and contract revenue was from AstraZeneca.
- R&D spending declined 24%, mainly as Phase 2B bremelanotide trial costs fell; general R&D also declined after Palatin closed its research laboratory facilities in July 2012.
- Net loss increased despite lower operating loss, principally because of a $7.1 million non-cash expense from the increase in fair value of warrants issued in the 2012 private placement.
- Operating cash use declined to $13.6 million. Financing cash inflow was $34.3 million, primarily from the private placement.
- Basic and diluted loss per share calculations included certain nominal-exercise-price warrants; the reported weighted-average share count therefore substantially exceeds the period-end common shares outstanding.
Outlook, commentary and risks
- Palatin reported statistically significant Phase 2B improvements in satisfying sexual events and measures of sexual functioning and distress for bremelanotide versus placebo. Common adverse events included flushing, nausea and vomiting; no serious adverse event was attributed to treatment in that trial.
- Management planned to begin pivotal Phase 3 trials in the first quarter of calendar 2014, subject to securing adequate funding or commitments. The planned program included two placebo-controlled trials, each targeting 600 evaluable patients; the company did not intend to begin patient enrollment without funding sufficient to complete the program.
- AstraZeneca discontinued AZD2820 after a Phase 1 trial was halted following a serious adverse event; a link to the drug could not be excluded. AstraZeneca was evaluating its remaining collaboration compounds, and continued development was uncertain.
- Palatin has no significant recurring revenue and expects further losses. Key risks include financing and dilution, Phase 3 efficacy and safety, regulatory approval, manufacturing and supply arrangements, reimbursement and market acceptance, and reliance on partners and contractors.
- The company disclosed extensive potential dilution: 91.6 million shares underlying warrants as of September 26, 2013, including 67.5 million warrants exercisable at $0.01 per share, subject to provisions and ownership limits. Financing agreements also grant investors participation rights in certain future financings and impose change-of-control provisions.
- No material adverse legal proceeding was reported. The independent auditor issued an unqualified opinion; management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Whether Palatin secured sufficient financing or a development partner to fund the estimated $78 million bremelanotide Phase 3 program, and whether trial timing and costs changed.
- Subsequent Phase 3 trial design, enrollment, safety findings and efficacy results, as well as FDA feedback and any approval pathway changes.
- Current cash and investment balances, operating cash burn, financing activity and actual runway relative to management’s calendar-2014 estimate.
- Current warrant and other dilutive-security counts, exercise activity, ownership limits, and the potential effect on share count and stock price.
- AstraZeneca’s decisions on remaining licensed compounds and any resulting milestones, royalties or termination of the collaboration.